New Triple-Threat attack on aggressive lung cancer
NCT ID NCT06838208
Summary
This study is testing a new combination treatment for people newly diagnosed with extensive-stage small cell lung cancer, a fast-growing and aggressive form of the disease. It combines an immunotherapy drug (tislelizumab) with standard chemotherapy and radiation therapy. The main goal is to see if this three-part approach can better control the cancer and keep it from growing for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Cancer Hospital
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.